FOR IMMEDIATE RELEASE
Statement attributable to:
Bruce Siegel, MD, MPH
President and CEO
America’s Essential Hospitals
WASHINGTON—Recent actions by pharmaceutical manufacturers hinder access to affordable medications for millions of people who face financial hardships and defy clear statutory requirements that they provide drugs to 340B Drug Pricing Program covered entities.
These manufacturers have threatened punitive actions—including withholding 340B drugs to contract pharmacies—for failing to comply with arbitrary reporting requirements. These data requests have no clear link to program integrity. Rather, they seem to be little more than a fishing expedition.
The federal government already has sufficient safeguards in place to avoid duplicate discounts under Medicaid and the 340B program. Particularly concerning is that the manufacturers’ data requests unduly exceed the scope of these federal protections by including commercial and Medicare activity.
These requests also burden the same hospitals now on the front lines of our COVID-19 response and put access to vital medications at risk for millions of people disproportionately affected by the pandemic. We call on the Department of Health and Human Services to intervene and put an end to these unwarranted manufacturer requests.
# # #
About America’s Essential Hospitals
America’s Essential Hospitals is the leading champion for hospitals and health systems dedicated to high-quality care for all, including the most vulnerable. We support our more than 300 members with advocacy, policy development, research, and education. Communities depend on essential hospitals to provide specialized, lifesaving services; train the health care workforce; advance public health and health equity; and coordinate care. Essential hospitals innovate and adapt to lead the way to more effective and efficient care. Learn more at essentialhospitals.org.